Deep vein thrombosi. Other venous embolism and thrombosis
Conditions
Interventions
Intervention 1: Control group: Patients receive pre-filled syringes of enoxaparin (manufactured by Alborz Daroo company) at dose of 40 mg/day through subcutaneous route. Intervention 2: Intervention g
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age between 18 and 65 years old Padua risk score = 4 points Signing the informed consent form
Exclusion criteria
Exclusion criteria: Patients in shock state Acute kidney injury Chronic kidney injury History of hemorrhage in past one month Invasive surgical procedures which needs to enoxaparin discontinuation Pregnancy Lactation Thrombophilia Antithrombin deficiency Previous history of venous thrombosis Body mass index more than 35 kg/m2 Platelet less than 50000 cells/uL
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The activity level of anti factor Xa. Timepoint: Three hours after third doses. Method of measurement: Chromogenic assay. | — |
Secondary
| Measure | Time frame |
|---|---|
| Occurance rate of deep vein thrombosis. Timepoint: Daily. Method of measurement: Clinical examination and sonography is necessary cases.;Occurrence rate of adverse drug reactions. Timepoint: Daily. Method of measurement: Observation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Sahraei
Shahid Beheshti University of Medical Sciences
Outcome results
None listed